65 Search Results for: covid
-
Market Commentary: Trump Signs New Stimulus Package as Vaccine Distribution Continues
The new stimulus package approved by the House and Senate was signed by President Trump Sunday night. The president had proposed upping the aid to individuals to $2,000 after the bipartisan agreement had been reached. Garnering support for that proposal would likely have proven difficult and economic urgency made signing the bill the logical choice. The need for additional support was evidenced by a 1.2% decline in disposable income (Figure 1).
Read more -
17 Things You Need to Know About the New Stimulus Package
Congress passed the new $900 billion economic relief and spending bill on Monday. While most of the focus has been on a second round of relief payments to most Americans, there is plenty more in the 5,000-plus pages of the stimulus package.
Read more -
Market Commentary: New Support Package to Provide Assistance to Individuals, Businesses and More
The economic slowdown continues. Initial jobless claims climbed 885,000 last week. In the face of additional restrictions and heightened health risks, consumers have scaled back activity. Retail and food service sales dipped 1.1% last month (Figure 1).
Read more -
Market Commentary: First Vaccines Roll Out as Unemployment Claims Remain High
Initial jobless claims reached an 11-week high based on data reported last week. More than 850,000 workers filed initial unemployment claims (Figure 1). While processing delays around the Thanksgiving holiday affected the data, even after adjusting for the break it appears the economic lull continues.
Read more -
Market Commentary: S&P 500 Gains Nearly 11% Last Month After Promising Vaccine News
November turned out to be a month full of news. A surge of COVID-19 cases, the presidential election, vaccine announcements, and slowing economic growth all moved markets. The November employment report provided additional evidence economic growth is decelerating. The economy generated 245,000 new jobs, missing expectations of 463,000 (Figure 1). Unemployment inched lower to 6.7% supported by the slow job growth and more people leaving the labor force.
Read more -
Giving to Charity for the Holidays, Even Though It’s 2020
Chances are, between basting the turkey and watching the football during the holidays, you’ll find yourself giving to the causes and organizations you believe in. In the U.S., 30% of the year’s charitable giving is done in December, and 10% of the annual giving is just in those last three days of the year!
Read more -
Market Commentary: Dow and S&P Set Records, but Unemployment Still Rising
The economy seems poised to decelerate in coming weeks as data showed slowing economic improvement or outright reversals of the recovery. Income data was mixed. Disposable income fell 0.8% in October as government programs expired. Gains in employment pushed employee compensation up 0.7% as more people returned to work.
Read more -
Market Commentary: Rise in COVID-19 Cases Leads to Market Dip Before Holiday Shopping Season
Retail data were mixed last week. U.S. retail sales rose 0.3% in October and are now 5.7% higher than one year ago. But as Figure 1 shows, the increase was the smallest since the recovery began. Increased coronavirus cases in October likely pressured purchases lower and moved consumers online. Non-store retailers reported a 3.1% increase in sales.
Read more -
Market Commentary: Markets Respond Favorably to News of Second Vaccine’s Positive Results
Special Update A second COVID-19 vaccine announced very positive results in its initial trial. A biotechnology company announced Monday their COVID-19 vaccine was more than 94.5% effective. The study also showed there were few side effects observed in the vaccine trial. The effectiveness is very high and will likely give the world two vaccines to start protecting people in coming months.
Read more -
Market Commentary: COVID-19 Vaccine Shows Positive Results and Market Soars Even After Tight Election
Special Update The first COVID-19 vaccine to announce results reported very positive data early Monday morning. Two notable pharmaceutical and biotech companies announced on Monday their COVID-19 vaccine was more than 90% effective. The study also showed there were no side effects observed in the vaccine trial. The effectiveness is higher than many medical experts expected and represents a major step forward in efforts to contain the virus. News on other vaccine trials is expected in coming weeks and months.
Read more